A missense variant in specificity protein 6 (SP6) is associated with amelogenesis imperfecta by Smith, C.E.L. et al.
This is a repository copy of A missense variant in specificity protein 6 (SP6) is associated 
with amelogenesis imperfecta.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/162040/
Version: Published Version
Article:
Smith, C.E.L., Whitehouse, L.L.E., Poulter, J.A. et al. (8 more authors) (2020) A missense 
variant in specificity protein 6 (SP6) is associated with amelogenesis imperfecta. Human 
Molecular Genetics, 29 (9). pp. 1417-1425. ISSN 0964-6906 
https://doi.org/10.1093/hmg/ddaa041
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1417
Human Molecular Genetics, 2020, Vol. 29, No. 9 1417–1425
doi: 10.1093/hmg/ddaa041
Advance Access Publication Date: 13 March 2020
General Article
GENERA L ART I C L E
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Abstract
Amelogenesis is the process of enamel formation. For amelogenesis to proceed, the cells of the inner enamel epithelium
(IEE) must first proliferate and then differentiate into the enamel-producing ameloblasts. Amelogenesis imperfecta (AI) is a
heterogeneous group of genetic conditions that result in defective or absent tooth enamel. We identified a 2 bp variant
c.817_818GC>AA in SP6, the gene encoding the SP6 transcription factor, in a Caucasian family with autosomal dominant
hypoplastic AI. The resulting missense protein change, p.(Ala273Lys), is predicted to alter a DNA-binding residue in the first
of three zinc fingers. SP6 has been shown to be crucial to both proliferation of the IEE and to its differentiation into
ameloblasts. SP6 has also been implicated as an AI candidate gene through its study in rodent models. We investigated the
effect of the missense variant in SP6 (p.(Ala273Lys)) using surface plasmon resonance protein-DNA binding studies. We
identified a potential SP6 binding motif in the AMBN proximal promoter sequence and showed that wild-type (WT) SP6
binds more strongly to it than the mutant protein. We hypothesize that SP6 variants may be a very rare cause of AI due to
the critical roles of SP6 in development and that the relatively mild effect of the missense variant identified in this study is
sufficient to affect amelogenesis causing AI, but not so severe as to be incompatible with life. We suggest that current AI
cohorts, both with autosomal recessive and dominant disease, be screened for SP6 variants.
†Indicates joint senior authorship.
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Introduction
Enamel is nature’s most extreme example of biomineralization
in humans. It results in a substance that is over 95% mineral
by weight (1), a much greater content than for other examples
of biomineralization, such as dentine (70%) or bone (65%) (2).
Amelogenesis is the process of enamel formation. It begins
with secretion by ameloblasts, the cells that form enamel, of
a proteinaceous enamel matrix, created to the full thickness
of the future enamel. This is then progressively mineralized
through a series of repeated, cyclical processes. These involve
the breakdown and removal of the enamel matrix proteins and
the growth of calciumhydroxyapatite crystals to form the prisms
that give enamel its hardness.
However, for amelogenesis to begin, reciprocal signaling, both
to and from the future enamel-producing dental epithelium
and the future dentine-producing mesenchyme, is required to
initiate the final stages of pre-ameloblast differentiation into
ameloblasts (3,4). This means that the formation of dentine
and the initiation of amelogenesis are intrinsically linked. Pre-
odontoblasts polarize, undergo internal reorganization and exit
the cell cycle to become odontoblasts in response to signaling
from the epithelium (5). Odontoblasts secrete an initial pre-
dentine collagen matrix that, when it begins to mineralize,
prompts the pre-ameloblasts to elongate and to change their
polarity, so that their apical face is adjacent to the dental papilla
(5). Concomitantly, the pre-ameloblasts become post-mitotic
ameloblasts and secrete greater amounts of enamel matrix
proteins including ameloblastin, which is thought to act as an
adhesion molecule and anchor for ameloblast attachment to
the secreted enamel matrix (6). The factors implicated to date in
the control of the proliferation of the dental epithelium and the
differentiation of ameloblasts are numerous and include both
the RUNX2—NFIC—OSX (also known as SP7) transcription factor
pathway (7), the Sp6 transcription factor (8) and many other
transcription factors and signaling molecules. SP6 is also known
as specificity protein 6 or epiprofin and was previously called
Krüppel-like factor 14 (KLF14).
Amelogenesis imperfecta (AI) is a heterogeneous group of
genetic conditions characterized by defective enamel. AI can
be broadly classified based on the enamel phenotype, although
mixed phenotypes do occur. Defects at the start of or during
enamel matrix secretion tend to cause hypoplastic AI, where
the enamel is absent or thin and variably mineralized. Defects
during the maturation stage generally result in hypomineral-
ized AI, where the enamel is of full thickness but is weak and
inevitably fails prematurely. Hypomineralized AI has been fur-
ther subdivided into hypomaturation and hypocalcified AI that
produce brittle and soft enamel, respectively. AI may present
as an isolated phenotype or may be associated with other oral
or extra-oral features as part of a syndrome. The prevalence
of AI has been reported to be 1 in 700 in an isolated Swedish
population (9) and around 1 in 14000 in the US population (10).
Mutations in many genes are known to cause AI, and these
can be inherited in an autosomal recessive, dominant or X-
linkedmanner (11).Mutations in the genes encoding the enamel
matrix proteins (AMELX, AMBN and ENAM) and the enamel
proteinases (MMP20 and KLK4) were the first to be reported to
cause AI. Variants in other genes encoding proteins thatmediate
or affect cell adhesion (LAMA3, LAMB3, COL17A1, FAM83H and
ITGB6) or are thought to be involved in endocytosis, calcium
transport and pH sensing (WDR72, SLC24A4 and GPR68, respec-
tively) have also been implicated. Mutations in the gene encod-
ing transcription factor DLX3 and in genes encoding proteins for
which their function in amelogenesis is less clear (e.g. ODAPH,
AMTN, ACP4, RELT and FAM20A) are also known to cause AI.
Despite this, between 51 and 72% of AI cases are reported to
be genetically undiagnosed (12–14). However,mutations inmany
more genes have been identified as a cause of AI since some of
these studies were published and massively parallel sequencing
is in now routine use, so the detection rate at present is likely to
be higher than in those reports.
Herewe report a familywith dominantly inherited, hypoplas-
tic AI carrying a variant in the Sp6 transcription factor gene (SP6).
SP6 has been shown to be involved in ameloblast differentiation
(15) and regulation of tooth-related genes (16). It has also been
shown to be expressed during the secretory stage of amelogene-
sis (17) and in the pre-ameloblast inner enamel epithelium (IEE)
(18). We model the effect of the variant on protein function and
analyze its impact on SP6 binding to target gene promoters.
Results
Patient phenotype
We identified aWhite British family segregating autosomal dom-
inant hypoplastic AI in the absence of any clinically obvious
co-segregating health problems (Figure 1A).
Whole-exome sequencing, PCR and Sanger sequencing
To identify the cause of AI in this family, we performed whole
exome sequencing (WES) on DNA from individuals II:3, III:3 and
IV:2 (Figure 1A). Following alignment, processing and duplicate
removal, a mean depth of 56.71, 64.12 and 87.62 reads per base
was observed, respectively, for individuals II:3, III:3 and IV:1
with 98.3, 98.5 and 99.0% of bases covered by at least 5 reads,
respectively, (further alignment statistics are available in Supple-
mentary Material, Table S1). Indel and single nucleotide variants
were called in variant call format (VCF) using the Haplotype
Caller function of Genome Analysis Toolkit (GATK) (19).
Variants were selected based on the autosomal dominant
inheritance evident in the family (confirmed by male-to-male
transmission). The resulting variants were then filtered to select
those present in all three affected individuals (II:3, III:3 and IV:2)
and to exclude all changes other than missense, frameshift or
stop mutations, exonic insertions/deletions or variants located
at splice consensus sites.
In addition, variants present in gnomAD (v2.1.1) (20) were
excluded if present at a frequency higher than that determined
using the allele frequency app (http://cardiodb.org/allelefre
quencyapp/) (21). A filter frequency cutoff of 4.51× 10−5 was
obtained using the following input values (data accessed May
1, 2017): monoallelic disease, 1 in 700 prevalence (the highest
prevalence reported for AI (9)), an allelic heterogeneity value of
0.06 based on 132 reported autosomal dominant families, and
the most frequently reported variant, ENAM c.1259_1260insAG,
having been reported in 7 families to date (11). Genetic
heterogeneity was arbitrarily set to 1 as per app instructions.
This left 12 variants, of which only 8 segregated with
the disease phenotype after PCR and Sanger sequencing
of DNA from all available family members and segregation
analysis (Supplementary Material, Table S2). One further variant
(chr17:43553034G>A) in PLEKHM1 could not be confirmed nor
checked for segregation with disease due the presence of a near
identical pseudogene, PLEKHM1P. It is noteworthy that a rare
SNP (rs768117863) is present at the homologous position for
the variant in PLEKHM1P (chr17:62818453G>A). The sequences
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Figure 1. Family pedigree, dental phenotype, genotyping and conservation. (A) Pedigree of the British family investigated. Affected family members are shaded. WES
was carried out on the individuals marked with asterisk. Segregation analysis of the SP6 c.817_818GC>AA for all available family members is also shown. (B) The
permanent dentition of the index case, IV:2 (arrow on pedigree) was characterized by generalized hypoplastic AI with an irregular surface involving all teeth. Note: the
small soft tissue lesion involving the hard palate (markedwith asterisk) is a reactive lesion unrelated to the dentition. (C) Sanger sequencing electropherograms to show
the WT SP6 and the SP6 c.817_818GC>AA (NM_199262) variant sequence. (D) Conservation analysis of the p.Ala273 residue in orthologous and paralogous proteins.
of the two homologous exons are 98.8% identical, suggesting
that alignment quality might be compromised for these
positions.
Alongside variant calling, copy number variant (CNV) anal-
ysis was also performed, using ExomeDepth software (22). This
compares read depths across all captured exons of samples from
affected individuals (II:3, III:3 and IV:2) against the read depths of
10 samples fromunrelated individualswhoseDNAhad beenpro-
cessed within the sameWES batches, using identical conditions,
as the affected samples from the family. After filtering to select
only CNVs that occur in all three affected family members and
that were not also called in three unrelated individuals, one rare
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CNV (not in the Database of Genomic Variants (23)) in SIGLEC11
remained (Supplementary Material, Table S3).
Variant filtration in this family therefore appeared to exclude
the involvement of all AI genes known to date, suggesting the
involvement of a variant in a gene not previously implicated
in AI. Supplementary Material, Table S4 reviews the available
literature on the potential for involvement in AI of each of the 10
remaining candidate genes and variants. CALHM3, PCK2, KRT76,
NME8, RAB26 and SIGLEC11 are relatively tolerant of variation
(gene missense Z score≤ 0.35) making it unlikely that heterozy-
gous variants in these genes could cause Mendelian disease. For
five of these six candidates, there is no known involvement in
inherited disease of any sort, but polymorphisms in CALHM3
have been associated with susceptibility to Alzheimer disease
(24) and Creutzfeld-Jakob disease (25) and are known to be
involved in taste perception (26). Of the four remaining genes,
human disease is already associated with variants in PLEKHM1
(OMIM #611497 osteopetrosis) and EPOR (OMIM #133100 erythro-
cytosis), but the family presented here does not exhibit either
of these phenotypes. Very little is known about EFCC1, but again
there is no known link with tooth development or function or
involvement in any form of disease phenotype, either in humans
or in animal models.
Variants in the tenth candidate gene, SP6, have also not been
associated with disease in humans to date. However, SP6 is
known to have an essential role in ameloblast differentiation
and to regulate the expression of many tooth-related genes. Fur-
thermore, SP6 is already implicated in AI in a rat model carrying
an Sp6 2 bp insertion (27,28) and in two murine Sp6−/− models
(15,29). It has also previously been proposed as a candidate
gene for AI (Supplementary Material, Table S4) (28). Therefore,
of the variants that remained after segregation, the two base
pair missense variant in SP6, c.817_818GC>AA, p.(Ala273Lys)
(NM_199262.2,NP_954871.1)was prioritized for further investiga-
tion. This variant was absent in dbSNP150 and Genome Aggrega-
tionDatabase v.2.1.1 (gnomAD; accessed 08/02/2019). The variant
is predicted to affect a residue that lies within the first of
three C2H2 zinc finger domains and is highly conserved in SP6
orthologues in all species analysed and in all other SP family par-
alogues (Figure 1B). The p.(Ala273Lys) substitution is predicted
to be deleterious or damaging by Provean, SIFT and Polyphen-2
with a combined annotation-dependent depletion (CADD) (v1.3)
score of 33, suggesting that protein structure and/or function
may be affected.
Based on this result, we screened all known exons and
flanking intronic sequence of SP6 (based on NM_001258248
and NM_199262) in a further 35 dominant AI samples, but no
single nucleotide variants nor small indels in SP6were identified
(Supplementary Material, Table S5).
Protein structural analysis
Literature searching and database interrogation showed that SP6
consists of 376 amino acids and contains three ZnF domains
(His254 to His278 [25aa], Phe284 to His308 [25aa] and Phe314 to
His336 [23aa]) responsible for DNA binding (30). Within these
three ZnF domains, three particular residues per ZnF contact the
DNA. The variant identified here (p.(Ala273Lys)) alters a residue
in the first ZnF domain that is predicted to form a direct contact
with target DNA sequences (31). Therefore, p.(Ala273Lys) is likely
to cause disease by affecting the binding of mutant SP6 to DNA.
We searched the Protein Data Bank (PDB) for high-resolution
structures for SP6. Although SP6 does not currently have a struc-
ture file in PDB, there are NMR structures of the three ZnFs of
the highly homologous SP1 protein (Figure 1D). These structures
(PDB codes 1VA1, 1VA2 and 1VA3) show the position correspond-
ing to p.Ala273 on the solvent-exposed face of the ZnF α-helix.
Substitution with a large, polar side chain in this location is
unlikely to perturb protein folding as packing of the hydrophobic
core or zinc ion binding is unaffected.
Crystal structures of other Cys2His2 ZnF-DNA complexes, for
example, for GLI and ZIF268 (PDB codes 2GLI and 1ZAA, respec-
tively) allowed us to assess likely effects of the p.(Ala273Lys)
variant. These show the α-helix docking into the major groove
with contacts from various positions along the helix. Some
fingers show contact to DNA from the amino acid immediately
N-terminal to the His2 motif, including His, Val, Thr, Arg and
indeed Lys (Supplementary Material, Figure S1). With the C-
terminus of the α-helix (and the His2 motif) being relatively
solvent-exposed and with the flexibility of the lysine side chain,
it is not clear whether the increased volume of the p.(Ala273Lys)
change would strongly inhibit docking of the SP6mutant protein
with DNA.
Identification of candidate SP6 promoter motifs and
binding assays
Since SP6 is a transcription factor, we tested the effect of
the c.817_818GC>AA, p.(Ala273Lys) variant on target sequence
specificity and DNA binding through Biacore surface plasmon
resonance (SPR) binding assays. Searching JASPAR (32) showed
that the binding motif for SP6 is not known, but binding motifs
for SP1, 2, 3, 4 and 8 are reported (Supplementary Material, Table
S6). SP proteins are known to bind CG-rich promoter elements
in promoter proximal regions (33) and the motifs identified in
our search included GC boxes (GGGCGG), although these were
generally identified on the non-coding strand.We then searched
the proximal promoter sequences of known rodent SP6 target
genes Amtn, Rock1, Car3, Fst, Osr2 and Pcm1 (Utami et al (16)),
for sequences similar to the DNA motifs recognized by other
SP proteins. We identified a 9 bp CCCCGCCCC motif, which
contains the GC box sequence in antisense, within 101 bp or
fewer upstream of the transcriptional start sites of the human
genes ROCK1, CA3, FST and PCM1. Alternative shorter anti-sense
GC box-containing sequences and other CG rich regions were
identified upstream of the transcriptional start site of OSR2 (e.g.
CCCGCCC). No motif was identified within the proximal pro-
moter region ofAMTN. The CCCCGCCCCmotif has been reported
previously to be bound by SP1 (34) and has been associated with
nucleosome remodeling (35). This 9 bp motif should have a 50%
chance of occurring randomly once every 181 Kbp.
Another report presents evidence that SP6 may regulate
AMBN expression in mice, although direct binding of SP6 to
the Ambn promoter region was not assessed (15). We searched
the proximal promoter region of AMBN and identified an 8 bp
motif CCCGCCCC, similar to the 9 bp motif identified in the
other genes, at 97 bp upstream from the transcriptional start
site. Interestingly, this motif is within 4 bp of a second distal
GC-rich motif CCCCCCCGCCAC.
In addition, we searched the proximal promoter regions
of other known and candidate AI genes, as well as SP6 itself,
for potential SP6 binding sites. GC-rich motifs were identified
in the proximal promoter regions of FAM83H and SP6. No likely
motifs were identified in the promoters of known and candi-
date AI genes ACP4, AMELX, COL17A1, DLX3, ENAM, FAM20A,
GPR68, ITGB6, KLK4, LAMA3, LAMB3,MMP20,ODAM,ODAPH, RELT,
SLC10A7, SLC24A4, WDR72 and TUFT1. All motifs identified are
detailed in Supplementary Material, Table S7.
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Table 1. Affinity and kinetic values describing SP6-DNA binding to the AMBN oligonucleotide by Biacore SPR
KD (nM) ka (M
−1 s−1) kd (s
−1)
WT SP6 226 (±12) 2.18×104 (±0.005×104) 4.91× 10−3 (±0.18× 10−3)
Mutant SP6 295 (±77) 2.07×104 (±0.053×104) 5.68× 10−3 (±0.18× 10−3)
Values were determined by data fitting for all concentrations tested over 3-min injections and 5 min of dissociation (n=3)
Figure 2. Comparison of DNA-binding activity of WT and mutant SP6 proteins using Biacore SPR. Biotinylated oligonucleotides were captured on a streptavidin–
derivatized sensor chip surface. WT and mutant SP6 proteins were washed over these surfaces across a range of concentrations. Each 3-min injection was followed by
buffer washes to follow dissociation rates of the SP6-DNA complex. Sensorgram results are shown for the AMBN oligonucleotide (sequence in Supplementary Material,
Table S8) (A) WT SP6; (B) mutant SP6. DNA-binding by the mutant SP6 protein demonstrates that this variant does not abolish binding, consistent with the mutation
affecting only one of the three zinc finger motifs. However, the mutant does show reduced binding compared to the WT, with the dissociation rate for the mutant SP6
protein being faster than for the WT. This is clear on the AMBN promoter sequence surface with the signal dropping to lower values than for the WT protein.
Four biotinylated complementary probes were designed for
Biacore SPR studies of protein-DNA interactions (Supplemen-
tary Material, Table S8). The first three contain a putative SP6
binding motif from known SP6 bound target gene promoters;
ROCK1 (chr18:18691847–18691886 negative stand) (16,36), AMBN
(chr4:71457862–71457901 positive strand) (15) and CA3 (chr8:
86350989–86351028 positive strand) (16). The fourth contains a
region, GCCTCCGGGAGGC, known to bind SP3 within the NKX2-
1 promoter (chr14:36989530–36989569) (37) and was included to
test SP6 specificity.
To study the effect of the p.(Ala273Lys) variant in vitro, we
cloned and expressed WT and mutant SP6 proteins. SPR was
carried out using the four probes and a control underivatized
surface as a reference flow cell. SP6 WT and SP6 p.(Ala273Lys)
mutant proteins were injected over derivatized surfaces fol-
lowed by buffer to observe the binding and dissociation rates of
the DNA-protein complexes.
Neither WT nor mutant SP6 protein bound the NKX2-1 pro-
moter sequence (data not shown), supporting specificity for
an exclusively-GC SP6 binding motif. Both proteins bound the
ROCK1 and CA3 promoter sequences but gave low signals: 16
response units (RU) and 29 RU at maximum, respectively, for the
400 nM WT protein condition (Supplementary Material, Figure
S2). In contrast, strong binding was evident for WT and mutant
SP6 with the AMBN promoter sequence (228 RU and 154 RU,
respectively, at maximum for the 400 nM protein concentration),
as shown by the increasing signal with increasing concentration
(Figure 2, Additional File 1). This shows that this oligonucleotide
contains a relevant binding sequence for WT SP6. DNA-binding
by the mutant protein demonstrates that this allele does not
abolish this binding, consistent with themutation affecting only
one of the three zinc finger motifs. However, the mutant does
show reducedmaximal binding compared to theWT, a reduction
of around 32%. The difference in binding is largely due to a
significantly faster dissociation rate for the mutant protein-
DNA complex than the WT (Table 1). This is clear for the AMBN
promoter sequence surface, since the signal dropped at a faster
rate and to lower values than for the WT protein.
Discussion
We identified a family with autosomal dominant hypoplastic
AI in whom WES revealed a 2 bp variant, c.817_818GC>AA in
SP6, resulting in themissense change p.(Ala273Lys). PCR analysis
confirmed that the SP6 variant segregates with the disease phe-
notype along with eight other variants. A screen of 35 additional
dominant AI families revealed no further variants in SP6.
SP6 belongs to the SP transcription factor family and consists
of a proline rich N-terminal domain and a C terminal domain
containing three C2H2 zinc finger domains (31). The zinc finger
domains are believed to contact DNA via specific residues (38).
For the first of the three zinc fingers in SP6, these residues are
predicted by homology to be Lys267, His270 and Ala273 (31).
The variant identified in the family reported here changes the
small hydrophobic Ala273 residue to a large, hydrophilic residue,
potentially altering the structure of the first zinc finger domain
and also its function.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/h
m
g
/a
rtic
le
-a
b
s
tra
c
t/2
9
/9
/1
4
1
7
/5
8
0
4
9
0
6
 b
y
 g
u
e
s
t o
n
 1
8
 J
u
n
e
 2
0
2
0
1422 Human Molecular Genetics, 2020, Vol. 29, No. 9
Mutations in other SP family proteins have not been reported
except for SP7. A frameshift mutation in SP7 was reported in a
single case with autosomal recessive osteogenesis imperfecta
type XII (MIM #613849) (39). Similarly, three siblings with the
same disease were reported with a homozygous c.946C>T vari-
ant (40). This results in missense change p.(Arg316Cys) within
the first zinc finger of SP7, similar to the position of the mis-
sense variant in SP6 identified in this study (for reference, the
equivalent SP6 residue is p.Arg276). It is notable that one of
the heterozygous carrier parents also met the criteria for adult
osteoporosis, suggesting that missense variants affecting this
part of the protein may be sufficient to cause mild disease even
when one WT copy is present.
Rodent models of SP6 function include two murine SP6 null
(Sp6−/−) lines (15,29) and a rat (Ami/Ami) with a frameshift
mutation in the third zinc finger domain (NM_001108833.1:
c.965_966insGT, NP_001102303: p.F323Sfs∗12). The Sp6−/− mice
show either total absence of enamel or secretion of a thin
irregular enamel layer (29). The Ami/Ami rats have hypoplastic
AI (28), a similar phenotype to that of the family presented
here. The Sp6−/− mice also display a range of other phenotypes
including delayed tooth eruption, supernumerary teeth, fused
teeth, defective cusp formation, malformed roots and enlarged
dentine tubules as well as retarded growth, failure to develop fur
and abnormalities in limb development and lung alveolarization
(15,29). The phenotype of the Ami/Ami rat model appears to
be more restricted to enamel formation, although at birth,
whiskers are curly and are weak throughout adulthood (28).
Heterozygous Sp6+/− or Wt/Ami animal models do not display
an AI phenotype, but Sp6+/− mice have been reported to have a
wider enamel layer with an irregular and less compact structure
thanWT (15). SP6 has previously been highlighted as a candidate
gene for human AI, although autosomal recessive inheritance
was predicted based on the animal models (28). Based on the
information from animal models, the mutation itself appears
critical to the range of phenotypes seen and their severity. The
missense variant reported here may not be accurately modelled
by the Sp6−/− mouse or the Ami/Ami rat. It is also possible that a
gain of function may occur if DNA binding specificity or ability
is altered by the p.Ala273Lys substitution, as it does appear to be
from SPR studies.
Studies of Sp6−/− mice suggest that the function of SP6
in amelogenesis is dependent upon the developmental stage.
Firstly, SP6 promotes proliferation of the IEE, and secondly, it
stimulates the differentiation of these cells to form ameloblasts
(15). One murine Sp6 transcript (NM_031183) has been detected
in the posterior neuropore, the apical epidermal ridge of limb
buds and in teeth and hair follicles of murine embryos but not
in adult tissues (41), suggesting that the function of this SP6
transcript may be entirely developmental. The expression of
the other murine transcript, NM_001363230, which codes for an
identical protein, has been described as ubiquitous (31) although
an antisense transcript has also been detected, whichmay serve
to regulate expression levels, so that embryonic expression of the
protein is significantly higher than in the adult. Unfortunately,
no relative quantification of the three transcripts’ expression
levels in embryonic dental tissues has been demonstrated to
date,meaning that it is unclearwhether SP6 is expressed in adult
tissues.
Our attempts to examine the effect of the mutation on the
binding of SP6 to its target sequences have been hampered by
lack of knowledge of the sequences SP6 binds within its target
proximal promoter regions. Literature searching showed that
SP6 probably binds GC rich motifs such as GC boxes, and SPR
studies supported this. Of the motifs tested, the AMBN proximal
promoter sequence was most strongly bound. The binding for
the ROCK1 and CA3 promoter sequences was much lower in
comparison, perhaps suggesting that the proximity of other GC
rich sequences or the surrounding sequence context affects
binding efficiency. In addition, the lack of GC-rich sequence in
the AMTN proximal promoter region suggests that there might
be additional sequencemotifs towhich SP6 binds or that itmight
influence expression through other intermediates.
The AMBN promoter sequence was most strongly bound by
WT SP6. In comparison, mutant SP6 protein also bound the
oligonucleotide sequence but less strongly and it dissociated
faster than the WT protein. This indicates that while binding
was affected by the variant, its negative effect may be relatively
mild. Given the likely pleiotropic effect of a more damaging
variant on the action of a transcription factor involved in devel-
opment of multiple tissues and organs such as SP6, this may
explain why further variants in SP6 causing AI or other human
phenotypes have not been reported to date. A more damaging
variant may not be compatible with life. Interrogation of gno-
mAD identified only 9 high quality loss of function variants
in 10 individuals, with the highest reported allele frequency
being 1.549×10−5. Only three missense variants, (p.Thr77Asn,
p.His159Tyr and p.Glu337Gln) were reported to have been iden-
tified as homozygous, each in only one individual. None of
these variants are within the three zinc fingers domains, again
highlighting the importance of these domains to SP6 function.
Results from the SPR study suggest a mechanism by which
the c.817_818GC>AA SP6 variant may cause AI. Reduced binding
of mutant SP6 to the AMBN proximal promoter sequence in vivo
could reduce the transcription of AMBN during amelogenesis,
resulting in less AMBN protein present in the enamel matrix.
Perturbation of AMBN levels has been shown to affect the lev-
els of other proteins important in amelogenesis, for example,
MSX and AMELX (42) and to affect ameloblast adhesion to the
extracellular matrix (43). These alterations are known to result
in hypoplastic AI. Other SP6 transcriptional targets, in addition
to AMBN, may also be affected. Investigation of the effects,
of either the rat or murine Sp6 variants, on AMBN expression
in developing tooth buds from these models could be useful
in determining whether the location, timing or level of AMBN
expression is altered.
In conclusion, a missense variant in SP6 has been found to
segregate with AI in a family with autosomal dominant inheri-
tance. Given the prior evidence for the role of SP6 in amelogene-
sis, the phenotype observed in three rodentmodels and our data
on the impact of this variant on binding to a likely target DNA
sequence of a known AI disease gene encoding a protein critical
for correct enamel formation, we suggest that this missense
variant is almost certainly the causative variant in the family
described here. Nevertheless, this finding would benefit from
replication in other cohorts,making SP6 a strong candidate gene
for further screening in AI. However, we further hypothesize
that the relatively mild effect of the missense variant shown in
this study is sufficient to cause AI but not so severe as to be
incompatible with life, which may explain why SP6 variants are
rare as a cause of AI.
Materials and Methods
Patients
Affected individuals and family members were recruited
following informed consent in accordance with the principles
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outlined by the declaration of Helsinki, with local ethical
approval. Genomic DNA samples were obtained using Oragene
®
DNA sample collection kits (DNA Genotek, ONT, Canada)
according to the manufacturer’s instructions.
WES and analysis
Three micrograms of genomic DNA were processed according to
the Agilent SureSelect XT Library Prep protocol (Agilent Tech-
nologies, CA, USA). Sure Select Human All Exon V5 or V6 (Agi-
lent Technologies) was used as the capture reagent. Sequencing
was performed using a 150 bp paired-end protocol on an Illu-
mina HiSeq 3000 sequencer (4981 and 4982) (Illumina, CA, USA).
The resulting fastq files were aligned to the human reference
genome (GRCh37) using BWA (44). The alignment was processed
according to GATK best practice. Exome depth was used for CNV
analysis according to the developers’ guidelines (22).
All genomic coordinates are based on the GRCh37 human
reference genome. The reference gene sequence upon which
SP6 mutation nomenclature is based is RefSeq transcript
NM_199262.
The variant identified in this study has been submitted to the
Leiden Open Variant Database at http://dna2.leeds.ac.uk/LOVD/
variant ID: 0000000305.
Protein synthesis
The SP6 wild type and mutant (p.A273K) coding sequences
were synthesized (GeneWiz, South Plainfield, NJ, USA) in pUC57
with codon optimization for E. coli expression and then PCR-
amplified usingQ5DNApolymerase (NEB,Evry, France; 5′ primer:
AAGTTCTGTTTCAGGGTACCATGCTGACCGCCGTTTGTGGC, 3′
primer: CTGGTCTAGAAAGCTTTTAATTGCTCGGGGCAACGC).
Both were cloned into pOPINJ using the NEBulider HiFi assembly
to produce constructs pOPINJ_SP6 and pOPINJ_SP6mut, each
containing an N-terminal His-GST tag.
pOPINJ_SP6 was transformed into BL21 (DE3) pLysS (Agilent
Technologies, Santa Clara, CA, USA), grown in terrific broth (TB
with 100 μg/ml ampicillin and 34 μg/ml chloramphenicol) to an
OD600 of 0.6, induced with 0.4 mm IPTG and 10 μM ZnCl2 and
incubated for 18 h at 27◦C. Bacteria were harvested through
centrifugation at 4000g for 40 min, the pellet resuspended into
PBS+1% Triton X-100 and the bacteria lysed using sonication
(10 s on, 30 s off, for 10 bursts at amplitude 60%). The soluble
lysate was purified on an AKTA Pure (GE Healthcare, Little Chal-
font, UK) using nickel affinity chromatography with a HisTrap
HP 5 ml column into His elution buffer (20 mm Tris, 150 mm
NaCl, 5% glycerol and 400mm imidazole, pH 7.6) using a gradient
elution. His-GST-SP6 was further purified through ion exchange
on a HiTrapQ HP 1 ml column and eluted with a gradient elution
in 10 mm HEPES, 1 M NaCl, pH 7.5. Resulting elutions were
concentrated in a Pierce protein concentrator (10 K MWCO), and
the concentrated proteinwas aliquoted, frozen in liquid nitrogen
and stored at −80◦C.
pOPINJ_SP6mut was transformed into ArcticExpress (DE3)
cells (Agilent Technologies) and grown in TB (with 100 μg/ml
ampicillin and 50 μg/ml gentamicin) for 3 h at 30◦C. Cultures
were then equilibrated for 10 min at 12◦C prior to induction
with 0.4 mm IPTG and 10 μM ZnCl2 and incubated for 24 h at
12◦C. Bacteria were harvested through centrifugation at 4000g
for 40 min, and then the pellet was resuspended into lysis/wash
buffer (50 mm Tris, 300 mm NaCl, 20 mm imidazole, 5% glycerol,
pH 7.6). The bacteria were lysed using sonication as before. The
soluble lysate was purified using Ni2+ NTA agarose beads into
His elution buffers with varying imidazole concentration using
a step elution. Soluble His-GST-SP6mut protein was identified
at 80 and 160 mm imidazole and pooled. His-GST-SP6mut was
further purified through ion exchange on a HiTrapQ HP 1 ml
column and eluted with a gradient elution in 10 mm HEPES, 1 M
NaCl, pH 7.5. Resulting elutions were concentrated in a Pierce
protein concentrator (10 KMWCO), and the concentrated protein
was aliquoted, frozen in liquid nitrogen and stored at −80◦C.
DNA probe preparation
Four probes were designed for protein-DNA interaction studies
using SPR. Single forward strand DNA molecules were synthe-
sized and biotinylated (Sigma–Aldrich) on the 5′-end (Supple-
mentary Table S8). Reverse complementary strandswere synthe-
sized without biotinylation.
DNA oligos were dissolved at 100 μM in TE buffer. Single-
strand biotin-labelled and non-biotin-labelled DNA oligos were
diluted in TM buffer [10 mm Tris (pH 7.5) and 10 mm MgCl2] to
a final concentration of 10 μM, annealed at 95◦C for 1 min and
cooled slowly to room temperature. Annealed DNA probes were
kept at −20◦C before use.
Surface plasmon resonance
SPR experiments were performed on a Biacore 3000 instrument
(GE Healthcare). Biotinylated DNA probes at 10 nMwere immobi-
lized on streptavidin (SA) sensor chips (GE Healthcare) at a flow
rate of 5 μL/min, to give ∼500 response units (RU) of immobi-
lized DNA. The reference flow cell was underivatized. All ligand
immobilization was done in HEPES-buffered saline consisting of
10 mm HEPES (pH 7.5), 200 mm NaCl and 0.01% (v/v) surfactant
P-20. Analyte measurements were carried out at 25◦C and a flow
rate of 40 μL/min, using the same buffer. For SP6–DNA-binding
assays, 120 μL of IEX-purified SP6 (WT or p.A273K) was injected
across flow-cell surfaces in a two-fold ascending concentration
series, from 6.25 to 400 nM for 3 min. Subsequently, buffer was
washed over the surfaces to observe the dissociation rates of
the DNA-protein complexes. The chip surface was regenerated
between protein injections with a 40 μL 0.05% (w/v) SDS injec-
tion. Binding data were processed using double-referencing by
subtraction of signals from a reference flow cell and by sub-
traction of a buffer injection over each derivatized flow cell.
Binding data were analyzed using BIAevaluation 3.1 software
(GE Healthcare).
Supplementary Material
Supplementary material is available at HMG online.
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